SCHEMBL2373756

SCHEMBL2373756

Cc1ccc(C=CC(=O)N(Cc2ccc(N3CCOCC3)nc2)C(Cc2ccccc2)C(=O)N2CCC(Cc3ccccc3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
GAA P10253 3/20 0.40
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
P2RX7 Q99572 1/20 0.38
TACR2 P21452 1/20 0.38
CYP46A1 Q9Y6A2 1/20 0.38
BCHE P06276 1/20 0.38
MAOA P21397 1/20 0.38
ACHE P22303 1/20 0.38
MAOB P27338 1/20 0.38
FAAH O00519 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2373752 1.00 LMNA (0.49) LMNAKDM4EMAPTGAAGRIN2D
SCHEMBL2373754 1.00 LMNA (0.49) LMNAKDM4EMAPTGAAGRIN2D
SCHEMBL2375183 0.93 RAB9A (0.42) LMNAKDM4EMAPTMEN1ALDH1A1
SCHEMBL2375180 0.93 RAB9A (0.42) LMNAKDM4EMAPTMEN1ALDH1A1
SCHEMBL2375186 0.93 RAB9A (0.42) LMNAKDM4EMAPTMEN1ALDH1A1
SCHEMBL2376249 0.93 LMNA (0.42) LMNAKDM4EMAPTGAAGRIN2D
SCHEMBL2376252 0.93 LMNA (0.42) LMNAKDM4EMAPTGAAGRIN2D
SCHEMBL2376256 0.93 LMNA (0.42) LMNAKDM4EMAPTGAAGRIN2D
SCHEMBL2374023 0.92 GAA (0.39) LMNAKDM4EMAPTGAAGRIN2D
SCHEMBL2374025 0.92 GAA (0.39) LMNAKDM4EMAPTGAAGRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US claimed
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 LMNA 1347/4885KDM4E 1004/4885MAPT 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.